Wensink, G. Emerens http://orcid.org/0000-0002-4103-5811
Elferink, Marloes A. G.
May, Anne M.
Mol, Linda
Hamers, Patricia A. H.
Bakker, Sandra D.
Creemers, Geert-Jan
de Groot, Jan Willem B.
de Klerk, Gerty J.
Haberkorn, Brigitte C. M.
Haringhuizen, Annebeth W.
Hoekstra, Ronald
Hunting, J. Cornelis B.
Kerver, Emile D.
Mathijssen-van Stein, Danielle
Polée, Marco B.
Pruijt, Johannes F. M.
Quarles van Ufford-Mannesse, Patricia
Radema, Sandra
Rietbroek, Ronald C.
Simkens, Lieke H. J.
Tanis, Bea C.
ten Bokkel Huinink, Daan
Tjin-A-Ton, Manuel L. R.
Tromp-van Driel, Cathrien S.
Troost, Monique M.
van de Wouw, Agnes J.
van den Berkmortel, Franchette W. P. J.
van der Pas, Anke J. M.
van der Velden, Ankie M. T.
van Dijk, Marjan A.
van Dodewaard-de Jong, Joyce M.
van Druten, Edith B.
van Voorthuizen, Theo
Jan Veldhuis, Gerrit
Verheul, Henk M. W.
Vestjens, Hanneke J. H. M. J.
Vincent, Jeroen
Kranenburg, Onno W.
Punt, Cornelis J. A.
Vink, Geraldine R.
Roodhart, Jeanine M. L.
Koopman, Miriam http://orcid.org/0000-0003-1550-1978
Article History
Received: 12 March 2020
Revised: 24 August 2020
Accepted: 2 September 2020
First Online: 13 October 2020
Ethics approval and consent to participate
: For trial-based patients, patient inclusion criteria, informed consent and study protocols for the trials were published previously.<sup>13–15</sup> For population-based patients, pseudonymised clinical data on demographic characteristics, tumour characteristics and treatment information (type, response) were obtained from the Netherlands Cancer Registry. The privacy rights for patients were maintained. The study was performed in accordance with the Declaration of Helsinki.
: not applicable.
: The datasets generated during and analyzed during the current study are not publicly available due to the regulations of the Netherlands Cancer Registry but are available from the corresponding author or Netherlands Cancer Registry on reasonable request.
: The authors declare no conflict of interest. J.W.B.G. Institutional financial instructs (IFI): BMS, Pierre Fabre, Roche, MSD, Shire, Amgen; M.K. IFI: Amgen, Bayer, BMS, Merck-Serono, Nordic Farma, Roche, Servier, Sirtex, Sanofi-Aventis; Non-financial interests (NFI): advisory role ZON-MW, daily board member DCCG, P.I. PLCRC; CJAP IFI: Amgen, Roche; J.M.L.R. IFI: Servier, Merck, Bayer; T.v.V. NFI: Pfizer, Ipsen, Astellas, Roche, Bayer; H.V. IFI: Immunovo, Glycostem, Roche; G.R.V. IFI: Servier, Bayer, Merck, BMS, Lilly. All grants were unrelated to the study and paid to the individual’s institution.
: None.